What is Regeneron Pharmaceuticals's current net income?

The latest figure on the record is $1.95 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $4.5 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 9, 2026.

What was Regeneron Pharmaceuticals's net income for the quarter ended September 30, 2026?

$1.95 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95).

When did Regeneron Pharmaceuticals's net income last change?

The latest value on the record is $4.5 billion, dated December 31, 2025; before it the record holds $4.41 billion, dated December 31, 2024 and closed on December 31, 2025.

What was Regeneron Pharmaceuticals's net income before $4.5 billion?

$4.41 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov).

organization · fact

Regeneron Pharmaceuticals net income

As of November 9, 2026, the latest net income figure on the AsOf record for Regeneron Pharmaceuticals is $1.95 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). Regeneron Pharmaceuticals's latest full-year net income is $4.5 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared.

latest net income: $1.95 billionthe quarter ended September 30, 2026 · 1 source
full-year net income: $4.5 billionDecember 31, 2025 · 1 source

18 dated values, oldest first; the current one in colour. In United States dollar.

Every dated value

18 values · 1 current · supersededA later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.More in About →

Regeneron Pharmaceuticals net income: every dated value on the record, oldest first, with its dates, status, confidence and sources
value	valid fromThe day the value took effect, not the day it was published. A period figure (a year's revenue) is dated at the period's end.More in About →	valid to	confidenceHow well the sources support the value, from 0 to 1. A single primary source is asserted from 0.7; nothing below 0.5 is asserted; a dead or disagreeing source lowers it.More in About →	sourcesPrimary: the entity's own filing, feed or site. Secondary: a publisher reporting it. Each claim links every source it has, with the passage that states the value where one was read.More in About →
-$79.13 million: net income -79,129,000 United States dollar from 2008-12-31, claim clm_7DFF0FB9DC16 and its sources (superseded) to 2009-12-31 · sec.gov	2008-12-31	2009-12-31	0.95	sec.gov
-$67.83 million: net income -67,830,000 United States dollar from 2009-12-31, claim clm_4BD3F29C30C3 and its sources (superseded) to 2010-12-31 · sec.gov	2009-12-31	2010-12-31	0.95	sec.gov
-$104.47 million: net income -104,468,000 United States dollar from 2010-12-31, claim clm_9855FD3A29B1 and its sources (superseded) to 2011-12-31 · sec.gov	2010-12-31	2011-12-31	0.95	sec.gov
-$221.76 million: net income -221,760,000 United States dollar from 2011-12-31, claim clm_F3AAA9683DBE and its sources (superseded) to 2012-12-31 · sec.gov	2011-12-31	2012-12-31	0.95	sec.gov
$750.27 million: net income 750,269,000 United States dollar from 2012-12-31, claim clm_2F265702ECB5 and its sources (superseded) to 2013-12-31 · sec.gov	2012-12-31	2013-12-31	0.95	sec.gov
$424.36 million: net income 424,362,000 United States dollar from 2013-12-31, claim clm_945579B45ED0 and its sources (superseded) to 2014-12-31 · sec.gov	2013-12-31	2014-12-31	0.95	sec.gov
$348.07 million: net income 348,074,000 United States dollar from 2014-12-31, claim clm_D3F5BB8C7757 and its sources (superseded) to 2015-12-31 · sec.gov	2014-12-31	2015-12-31	0.95	sec.gov
$636.06 million: net income 636,056,000 United States dollar from 2015-12-31, claim clm_65C9343FBB71 and its sources (superseded) to 2016-12-31 · sec.gov	2015-12-31	2016-12-31	0.95	sec.gov
$895.52 million: net income 895,522,000 United States dollar from 2016-12-31, claim clm_AFF68BBC35BE and its sources (superseded) to 2017-12-31 · sec.gov	2016-12-31	2017-12-31	0.95	sec.gov
$1.2 billion: net income 1,198,511,000 United States dollar from 2017-12-31, claim clm_DC0177CB2929 and its sources (superseded) to 2018-12-31 · sec.gov	2017-12-31	2018-12-31	0.95	sec.gov
$2.44 billion: net income 2,444,400,000 United States dollar from 2018-12-31, claim clm_FCBDA03CE99C and its sources (superseded) to 2019-12-31 · sec.gov	2018-12-31	2019-12-31	0.95	sec.gov
$2.12 billion: net income 2,115,800,000 United States dollar from 2019-12-31, claim clm_272E08FDAC9C and its sources (superseded) to 2020-12-31 · sec.gov	2019-12-31	2020-12-31	0.95	sec.gov
$3.51 billion: net income 3,513,200,000 United States dollar from 2020-12-31, claim clm_0AB6F3A48383 and its sources (superseded) to 2021-12-31 · sec.gov	2020-12-31	2021-12-31	0.95	sec.gov
$8.08 billion: net income 8,075,300,000 United States dollar from 2021-12-31, claim clm_D26172E0F6F8 and its sources (superseded) to 2022-12-31 · sec.gov	2021-12-31	2022-12-31	0.95	sec.gov
$4.34 billion: net income 4,338,400,000 United States dollar from 2022-12-31, claim clm_2FCCACC23EDE and its sources (superseded) to 2023-12-31 · sec.gov	2022-12-31	2023-12-31	0.95	sec.gov
$3.95 billion: net income 3,953,600,000 United States dollar from 2023-12-31, claim clm_11400CA0B8A6 and its sources (superseded) to 2024-12-31 · sec.gov	2023-12-31	2024-12-31	0.95	sec.gov
$4.41 billion: net income 4,412,600,000 United States dollar from 2024-12-31, claim clm_4E27594C511A and its sources (superseded) to 2025-12-31 · sec.gov	2024-12-31	2025-12-31	0.95	sec.gov
$4.5 billion: net income 4,504,900,000 United States dollar from 2025-12-31, claim clm_7514724ED5E9 and its sources to present · sec.gov	2025-12-31	present	0.95	sec.gov

What replaced what

17 replacements

-$79.13 million2008-12-31 to 2009-12-31→-$67.83 millionfrom 2009-12-31
-$67.83 million2009-12-31 to 2010-12-31→-$104.47 millionfrom 2010-12-31
-$104.47 million2010-12-31 to 2011-12-31→-$221.76 millionfrom 2011-12-31
-$221.76 million2011-12-31 to 2012-12-31→$750.27 millionfrom 2012-12-31
$750.27 million2012-12-31 to 2013-12-31→$424.36 millionfrom 2013-12-31
$424.36 million2013-12-31 to 2014-12-31→$348.07 millionfrom 2014-12-31
$348.07 million2014-12-31 to 2015-12-31→$636.06 millionfrom 2015-12-31
$636.06 million2015-12-31 to 2016-12-31→$895.52 millionfrom 2016-12-31
$895.52 million2016-12-31 to 2017-12-31→$1.2 billionfrom 2017-12-31
$1.2 billion2017-12-31 to 2018-12-31→$2.44 billionfrom 2018-12-31
$2.44 billion2018-12-31 to 2019-12-31→$2.12 billionfrom 2019-12-31
$2.12 billion2019-12-31 to 2020-12-31→$3.51 billionfrom 2020-12-31
$3.51 billion2020-12-31 to 2021-12-31→$8.08 billionfrom 2021-12-31
$8.08 billion2021-12-31 to 2022-12-31→$4.34 billionfrom 2022-12-31
$4.34 billion2022-12-31 to 2023-12-31→$3.95 billionfrom 2023-12-31
$3.95 billion2023-12-31 to 2024-12-31→$4.41 billionfrom 2024-12-31
$4.41 billion2024-12-31 to 2025-12-31→$4.5 billionfrom 2025-12-31

Questions this record answers

What is Regeneron Pharmaceuticals's current net income?: The latest figure on the record is $1.95 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $4.5 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 9, 2026.
What was Regeneron Pharmaceuticals's net income for the quarter ended September 30, 2026?: $1.95 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95).
When did Regeneron Pharmaceuticals's net income last change?: The latest value on the record is $4.5 billion, dated December 31, 2025; before it the record holds $4.41 billion, dated December 31, 2024 and closed on December 31, 2025.
What was Regeneron Pharmaceuticals's net income before $4.5 billion?: $4.41 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov).

Answered from the rows above, as of November 9, 2026.

Cite Regeneron Pharmaceuticals net income

Each form names the value, its as-of date (2026-09-30), the day you read it (2026-11-09), the claim's stable URL and id and its primary source. The URL never changes: a superseded claim stays at the same address.

Plain text

AsOf. "Regeneron Pharmaceuticals quarterly net income: 1,948,700,000 United States dollar", as of 2026-09-30. Claim clm_DEF587D6916A, https://asof.is/claim/clm_DEF587D6916A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.

APA

AsOf. (2026). Regeneron Pharmaceuticals quarterly net income: 1,948,700,000 United States dollar (as of 2026-09-30) [Record clm_DEF587D6916A]. Retrieved November 9, 2026, from https://asof.is/claim/clm_DEF587D6916A (source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm)

BibTeX

@misc{asof_clm_DEF587D6916A,
  author = {AsOf},
  title = {Regeneron Pharmaceuticals quarterly net income: 1,948,700,000 United States dollar},
  year = {2026},
  howpublished = {\url{https://asof.is/claim/clm_DEF587D6916A}},
  note = {Claim clm\_DEF587D6916A, as of 2026-09-30; source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm},
  urldate = {2026-11-09}
}

Read on

/record/regeneron-pharmaceuticals/net_income.md · this page as markdown
/facts/net_income · every company's net income
/record/regeneron-pharmaceuticals · /timelines/regeneron-pharmaceuticals

Other facts about Regeneron Pharmaceuticals

Record